Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CNTA
CNTA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CNTA News
Centessa Pharmaceuticals Officer Plans to Sell $3.1 Million in Common Stock via Form 144
Mar 13 2026
moomoo
Investment Comparison: Centessa vs. Vertex Pharmaceuticals
Feb 26 2026
Fool
Commodore Capital Reduces Stake in Centessa Pharmaceuticals
Feb 23 2026
Fool
Braidwell Acquires Significant Stake in Centessa Pharmaceuticals
Feb 19 2026
Fool
Tanager Wealth Management Fully Exits Centessa Pharmaceuticals Stake
Feb 02 2026
Fool
Tanager Wealth Management Exits Entire CNTA Position
Feb 02 2026
NASDAQ.COM
Centessa Pharmaceuticals Presents New OX2R Agonist Data, Enhancing Mood in Depression Models
Jan 14 2026
Globenewswire
Centessa Pharmaceuticals (CNTA) Shares Hit $22.44 with RSI at 28.4, Indicating Oversold Condition
Jan 05 2026
NASDAQ.COM
U.S. Stocks Rise, NVIDIA Target Price Set at $250
Jan 05 2026
Benzinga
Centessa Pharmaceuticals Appoints Accardi as CEO, Focusing on Orexin Drug Development
Dec 11 2025
Globenewswire
Centessa Pharmaceuticals Appoints Accardi as CEO, Focusing on Orexin Drug Development
Dec 11 2025
Newsfilter
Centessa Pharmaceuticals CEO Saurabh Saha Resigns; Mario Accardi Appointed as Successor
Dec 11 2025
NASDAQ.COM
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?
Nov 18 2025
NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
Nov 18 2025
NASDAQ.COM
Wells Fargo Keeps Overweight Rating on Centessa Pharmaceuticals and Increases Price Target to $35
Nov 13 2025
Benzinga
Centessa Pharmaceuticals Stock Rises 17% Following $250 Million Public Offering Announcement
Nov 12 2025
NASDAQ.COM
Show More News
